David A. Van Echo

3.8k total citations · 1 hit paper
71 papers, 3.0k citations indexed

About

David A. Van Echo is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David A. Van Echo has authored 71 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 29 papers in Molecular Biology and 17 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David A. Van Echo's work include Cancer therapeutics and mechanisms (22 papers), Cancer Treatment and Pharmacology (18 papers) and Lung Cancer Research Studies (16 papers). David A. Van Echo is often cited by papers focused on Cancer therapeutics and mechanisms (22 papers), Cancer Treatment and Pharmacology (18 papers) and Lung Cancer Research Studies (16 papers). David A. Van Echo collaborates with scholars based in United States, Malaysia and Australia. David A. Van Echo's co-authors include Merrill J. Egorin, Joseph Aisner, Peter H. Wiernik, Margaret Whitacre, Ross C. Donehower, Daniel D. Von Hoff, R. Gralla, D L Trump, T Ohnuma and James R. Baker and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Internal Medicine and JNCI Journal of the National Cancer Institute.

In The Last Decade

David A. Van Echo

70 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Hypersensitivity reactions from taxol.

1990 951 citations R B Weiss, Ross C. Donehower et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David A. Van Echo

Since Specialization

Citations

This map shows the geographic impact of David A. Van Echo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Van Echo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Van Echo more than expected).

Fields of papers citing papers by David A. Van Echo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Van Echo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Van Echo. The network helps show where David A. Van Echo may publish in the future.

Co-authorship network of co-authors of David A. Van Echo

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Van Echo. A scholar is included among the top collaborators of David A. Van Echo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Van Echo. David A. Van Echo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The significance of circulating epithelial cells in Breast Cancer patients by a novel negative selection method 2007 ·Breast Cancer Research and Treatment ·Katherine H. R. Tkaczuk, Olga Goloubeva, Nancy Tait, (unknown), Ming Tan, Zhao-Ping Lum, Stephen A. Lesko, David A. Van Echo, Paul O. P. Ts’o	24
2	Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer 2003 ·Cancer Chemotherapy and Pharmacology ·Robert I. Haddad, David A. Van Echo	6
3	Combination Nonviral Interleukin 2 Gene Therapy and External-Beam Radiation Therapy for Head and Neck Cancer 2003 ·Archives of Otolaryngology - Head and Neck Surgery ·David A. Bray, (unknown), Hilary Koprowski, Juong G. Rhee, Sanjeev Kumar, Federica Pericle, Mohan Suntharalingam, David A. Van Echo, Daqing Li, Bert W. O’Malley	12
4	Pleurx Tunneled Catheter in the Management of Malignant Ascites 2001 ·Journal of Vascular and Interventional Radiology ·Howard M. Richard, Douglas M. Coldwell, Robin Boyd-Kranis, Ravi Murthy, David A. Van Echo	62
5	The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck 2000 ·International Journal of Radiation OncologyBiologyPhysics ·Mohan Suntharalingam, Michael L. Haas, Barbara A. Conley, Merrill J. Egorin, (unknown), (unknown), Joseph M. Herman, (unknown), William C. Gray, Robert A. Ord, Joseph Aisner, David A. Van Echo	79
6	Phase I study of docetaxel and topotecan in patients with solid tumors 2000 ·Cancer Chemotherapy and Pharmacology ·Katherine H. R. Tkaczuk, William C. Zamboni, Nancy Tait, L. Austin Doyle, Martin J. Edelman, P Hausner, (unknown), David A. Van Echo, Barry Meisenberg	6
7	Phase I clinical trial of all-trans-retinoic acid with correlation of its pharmacokinetics and pharmacodynamics 1997 ·Cancer Chemotherapy and Pharmacology ·Barbara A. Conley, Merrill J. Egorin, Rajeshwari Sridhara, Rebecca S. Finley, (unknown), Suhlan Wu, Nancy Tait, David A. Van Echo	64
8	A phase trial of etoposide and cisplatin in extensive small cell lung cancer: A cancer and Leukemia Group B study 1996 ·Lung Cancer ·Edith Mitchell, Michael C. Perry, Sharon D. Luikart, Constance Cirrincione, David A. Van Echo, James E. Herndon, L. Herbert Maurer, Gerald H. Clamon, Mark R. Green	4
9	Phase I trial of chloroguinoxaline sulfonamide, with correlation of its pharmacokinetics and pharmacodynamics 1995 ·Cancer Chemotherapy and Pharmacology ·Barbara A. Conley, Susan O’Hara, (unknown), Teresa J. Melink, Howard L. Parnes, (unknown), Merrill J. Egorin, David A. Van Echo	8
10	Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. 1995 ·Journal of Clinical Oncology ·Mark J. Ratain, Guy Rosner, Steven L. Allen, (unknown), David A. Van Echo, I. Craig Henderson, Richard L. Schilsky	36
11	Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a Cancer and Leukemia Group B study 1995 ·Cancer Chemotherapy and Pharmacology ·Ronald A. Fleming, Robert L. Capizzi, Gary L. Rosner, Lawrence K. Oliver, Stephen J. Smith, Charles A. Schiffer, Richard T. Silver, B. A. Peterson, Raymond B. Weiss, George Omura, Robert J. Mayer, David A. Van Echo, Clara D. Bloomfield, Richard L. Schilsky	25
12	Phase I/II Trial of Etoposide and Carboplatin in Extensive Small-Cell Lung Cancer 1993 ·American Journal of Clinical Oncology ·Sharon D. Luikart, (unknown), (unknown), David A. Van Echo, Caron Modeas, Kathleen J. Propert, Joseph O’Donnell, Santo M. DiFino, Michael C. Perry, Mark R. Green	13
13	Phase I Trial of Granulocyte--Macrophage Colony-Stimulating Factor Plus High-Dose Cyclophosphamide Given Every 2 Weeks: a Cancer and Leukemia Group B Study 1993 ·JNCI Journal of the National Cancer Institute ·Stuart M. Lichtman, Mark J. Ratain, David A. Van Echo, Gary L. Rosner, Merrill J. Egorin, D. R. Budman, Nicholas J. Vogelzang, Larry Norton, Richard L. Schilsky	31
14	Approaches to optimal dosing of hexamethylene bisacetamide 1992 ·Cancer Chemotherapy and Pharmacology ·Barbara A. Conley, Merrill J. Egorin, Victoria J. Sinibaldi, (unknown), (unknown), (unknown), Eleanor G. Zuhowski, Alan Forrest, David A. Van Echo	17
15	Cisplatin, doxorubicin, cyclophosphamide, and etoposide combination chemotherapy for small-cell lung cancer 1992 ·Cancer Chemotherapy and Pharmacology ·Joseph Aisner, Margaret Whitacre, Daniel R. Budman, (unknown), Gary M. Strauss, David A. Van Echo, Michael C. Perry	14
16	Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study. 1990 ·Journal of Clinical Oncology ·David Parkinson, (unknown), Peter H. Wiernik, Anthony A. Rayner, Kim Margolin, David A. Van Echo, Mario Sznol, Janice P. Dutcher, Frederick R. Aronson, James H. Doroshow	163
17	Hypersensitivity reactions from taxol. breakdown → 1990 ·Journal of Clinical Oncology ·R B Weiss, Ross C. Donehower, Peter H. Wiernik, T Ohnuma, R. Gralla, D L Trump, James R. Baker, David A. Van Echo, Daniel D. Von Hoff, B Leyland-Jones	951
18	Phase II Trial of N-Methylformamide in Advanced Renal Cancer 1989 ·American Journal of Clinical Oncology ·Jeffrey S. Abrams, Nancy Tait, (unknown), Mario A. Eisenberger, David A. Van Echo, Ian Olver, Joseph Aisner	4
19	Plasma pharmacokinetics and urinary excretion of hexamethylene bisacetamide metabolites. 1987 ·PubMed ·Merrill J. Egorin, Eleanor G. Zuhowski, (unknown), (unknown), Patrick S. Callery, David A. Van Echo	9
20	Human Pharmacokinetics and Correlation With Clinical Toxicities of the Anthracycline Antibiotic Menogaril (7-Omen) 1985 ·Journal of Bioresource Management ·Merrill J. Egorin, David A. Van Echo, Margaret Whitacre, Kathrin L. Engisch, Eve A. Olman, (unknown), Alan Forrest, Joseph Aisner	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact